anti-EGFRvIII-CAR-CD3/EGFR BiTE-transduced autologous T lymphocytes CARv3-TEAM-E
Term · Oncology and biomedicine · MLC-T-ONC-010619
A preparation of autologous human T lymphocytes transduced with a CARv3-TEAM-E lentiviral vector encoding for an anti-epidermal growth factor receptor (EGFR) variant III (EGFRvIII) mutant chimeric T-cell receptor (chimeric antigen receptor or CAR) and a T-cell-engaging antibody molecule (TEAM) which comprises a bispecific T-cell engager (BiTE) against EGFR and the T-cell signaling domain CD3, with potential immunostimulatory and antineoplastic activities. Upon administration via Ommaya reservoir of the anti-EGFRvIII CAR-CD3/EGFR BiTE-transduced autologous T lymphocytes CARv3-TEAM-E, the lymphocytes bind to the EGFRvIII antigen on tumor cell surfaces and the BiTE binds to CD3 on bystander T cells; thereby killing EGFRvIII-expressing tumor cells through the administered CAR-T cells and wild-type (WT) EGFR-expressing tumor cells by bystander T cells, respectively. EGFRvIII, an in-frame deletion of exons 2-7 in the EGFR gene, is overexpressed by a variety of cancer cell types and absent in normal, healthy cells; it plays a key role in tumor cell proliferation, tumor angiogenesis and radio- and chemoresistance.
| Identifier | MLC-T-ONC-010619 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | autologous CARv3-TEAM-E-transduced T cells; autologous CARv3-TEAM-E-transduced T lymphocytes |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-010619",
"term": "anti-EGFRvIII-CAR-CD3/EGFR BiTE-transduced autologous T lymphocytes CARv3-TEAM-E",
"field": "Oncology and biomedicine",
"definition": "A preparation of autologous human T lymphocytes transduced with a CARv3-TEAM-E lentiviral vector encoding for an anti-epidermal growth factor receptor (EGFR) variant III (EGFRvIII) mutant chimeric T-cell receptor (chimeric antigen receptor or CAR) and a T-cell-engaging antibody molecule (TEAM) which comprises a bispecific T-cell engager (BiTE) against EGFR and the T-cell signaling domain CD3, with potential immunostimulatory and antineoplastic activities. Upon administration via Ommaya reservoir of the anti-EGFRvIII CAR-CD3/EGFR BiTE-transduced autologous T lymphocytes CARv3-TEAM-E, the lymphocytes bind to the EGFRvIII antigen on tumor cell surfaces and the BiTE binds to CD3 on bystander T cells; thereby killing EGFRvIII-expressing tumor cells through the administered CAR-T cells and wild-type (WT) EGFR-expressing tumor cells by bystander T cells, respectively. EGFRvIII, an in-frame deletion of exons 2-7 in the EGFR gene, is overexpressed by a variety of cancer cell types and absent in normal, healthy cells; it plays a key role in tumor cell proliferation, tumor angiogenesis and radio- and chemoresistance.",
"synonyms": [
"autologous CARv3-TEAM-E-transduced T cells",
"autologous CARv3-TEAM-E-transduced T lymphocytes"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/anti-egfrviii-car-cd3-egfr-bite-transduced-autologous-t-lymphocytes-carv3-team-e/"
}
Record 1,715 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.